It improves an addict's chances of staying clean for life. Research began in the early 60s into Ibogaine's potential use as a rehabilitation therapy for addicts but was abandoned after fears were raised over the safety of the drug. The FDA banned Ibogaine in 1967 due to its hallucinogenic properties. In 1995, researchers at the University of Miami managed to get permission from the FDA to study Ibogaine's effects on addicts but the funding eventually fell through. Big Pharma, and specifically the manufacturers of Methadone are thought to have had a hand in ensuring Ibogaine remains illegal so as to ensure their drug remains the number one treatment for heroin addiction.
Advocates of Ibogaine point out that far fewer side effects have been linked to the hallucinogen than to other rehabilitative drugs such as Methadone. Current treatments for substance addiction are largely ineffective and only one new drug known as Buprenorphine has been developed in the last two decades to treat opiate addiction.